CORVUS PHARMACEUTICALS INC (CRVS) Stock Fundamental Analysis
NASDAQ:CRVS - Nasdaq - US2210151005 - Common Stock
Overall CRVS gets a fundamental rating of 1 out of 10. We evaluated CRVS against 572 industry peers in the Biotechnology industry. The financial health of CRVS is average, but there are quite some concerns on its profitability. CRVS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CRVS has reported negative net income.
In the past year CRVS has reported a negative cash flow from operations.
CRVS had negative earnings in each of the past 5 years.
In the past 5 years CRVS always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -96.63%, CRVS is not doing good in the industry: 74.51% of the companies in the same industry are doing better.
CRVS's Return On Equity of -458.00% is on the low side compared to the rest of the industry. CRVS is outperformed by 79.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -96.63% | ||
| ROE | -458% | ||
| ROIC | N/A |
ROA(3y)-53.13%
ROA(5y)-44.45%
ROE(3y)-62.66%
ROE(5y)-52.39%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CRVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for CRVS has been increased compared to 1 year ago.
Compared to 5 years ago, CRVS has more shares outstanding
There is no outstanding debt for CRVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -6.30, we must say that CRVS is in the distress zone and has some risk of bankruptcy.
CRVS's Altman-Z score of -6.30 is on the low side compared to the rest of the industry. CRVS is outperformed by 67.26% of its industry peers.
There is no outstanding debt for CRVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.3 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.92 indicates that CRVS may have some problems paying its short term obligations.
The Current ratio of CRVS (0.92) is worse than 89.03% of its industry peers.
CRVS has a Quick Ratio of 0.92. This is a bad value and indicates that CRVS is not financially healthy enough and could expect problems in meeting its short term obligations.
CRVS has a Quick ratio of 0.92. This is amonst the worse of the industry: CRVS underperforms 87.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.92 | ||
| Quick Ratio | 0.92 |
3. Growth
3.1 Past
CRVS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -40.63%.
EPS 1Y (TTM)-40.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-400%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, CRVS will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.45% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-65.48%
EPS Next 2Y4.94%
EPS Next 3Y-6.1%
EPS Next 5Y13.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CRVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRVS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as CRVS's earnings are expected to decrease with -6.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.94%
EPS Next 3Y-6.1%
5. Dividend
5.1 Amount
CRVS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CORVUS PHARMACEUTICALS INC
NASDAQ:CRVS (1/21/2025, 8:00:00 PM)
After market: 4.9001 -0.32 (-6.13%)5.22
+0.21 (+4.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners27.83%
Inst Owner Change0.01%
Ins Owners4.02%
Ins Owner Change0%
Market Cap335.44M
Analysts87.27
Price Target16.07 (207.85%)
Short Float %10.54%
Short Ratio4.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-169.29%
Min EPS beat(2)-404.49%
Max EPS beat(2)65.9%
EPS beat(4)2
Avg EPS beat(4)-85.27%
Min EPS beat(4)-404.49%
Max EPS beat(4)65.9%
EPS beat(8)5
Avg EPS beat(8)-41.42%
EPS beat(12)6
Avg EPS beat(12)-37.6%
EPS beat(16)8
Avg EPS beat(16)-27.34%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)55.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.15%
EPS NY rev (1m)0%
EPS NY rev (3m)-133.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 27.03 | ||
| P/tB | 27.03 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.9
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -96.63% | ||
| ROE | -458% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-53.13%
ROA(5y)-44.45%
ROE(3y)-62.66%
ROE(5y)-52.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.92 | ||
| Quick Ratio | 0.92 | ||
| Altman-Z | -6.3 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)32.55%
Cap/Depr(5y)22.88%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-400%
EPS Next Y-65.48%
EPS Next 2Y4.94%
EPS Next 3Y-6.1%
EPS Next 5Y13.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.01%
OCF growth 3YN/A
OCF growth 5YN/A